real-time news and commentary for investors
Friday, Aug 10
2012, 2:41 PM
Wall Street firms are responding today to Sagent Pharmaceuticals' (SGNT -2.6%) revised outlook...
Wall Street firms are responding today to Sagent Pharmaceuticals' (SGNT -2.6%) revised outlook yesterday, which took the shares down over 25% during the trading session. RBC cut the shares to Sector Perform on the news, citing a lack of earnings visibility over the near term, while Needham, cut its price target to $20 from $25, saying the company "remains its own worst enemy" when it comes to managing estimates and maintaining management's credibility.